Max Higgins, Senior Consultant

BARDA RFP – Marburg Virus and Sudan Ebolavirus Vaccine Licensure and Procurement On July 12, 2025, the Biomedical Advanced Research and Development Authority (BARDA) issued Request for Proposals (RFP) #75A50125R00006. This RFP seeks proposals for the advanced development, FDA licensure, and procurement of vaccines targeting Marburg virus (MARV) and Sudan ebolavirus (SUDV). With recent outbreaks

Request for Proposals (RFP) for Antibiotic for Treatment of Bacterial Pneumonia or Bloodstream Infections Bolstering Biodefense with Advanced Antibiotics: BARDA’s Strategic Move As the threat of antibiotic-resistant infections intensifies, the U.S. Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), has issued a pivotal solicitation under Project BioShield

Advancing Burn Care Preparedness: BARDA’s Strategic Investment in Enzymatic Debridement Products In its ongoing mission to strengthen the nation’s biodefense and emergency response infrastructure, the Biomedical Advanced Research and Development Authority (BARDA), an office within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, has released a

Preparing for the Next Biological Threat: BARDA’s Vaccine Initiative for MARV and SUDV The Biomedical Advanced Research and Development Authority (BARDA), operating under the U.S. Department of Health and Human Services (HHS), has issued a pre-solicitation notice signaling its intent to launch a major Request for Proposal (RFP) later this year. This effort, managed by